Hepbest
Hepbest (Tenofovir Alafenamide 25mg) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor. It helps control the infection by reducing the amount of hepatitis B virus in your body, leading to decreased liver damage and improved liver function. It is a prodrug of tenofovir designed to deliver the active drug to hepatocytes more efficiently than Tenofovir Disoproxil Fumarate (TDF), thereby reducing systemic exposure and associated bone and renal toxicities.
Dosage by Body Weight
The standard dose for adults and pediatric patients (12 years of age and older, weighing at least 35 kg) is one 25 mg tablet taken orally once daily with food. Consult a healthcare provider for precise administration instructions.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients weighing less than 35 kg.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients weighing less than 35 kg.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients weighing less than 35 kg.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients weighing less than 35 kg.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients weighing less than 35 kg.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients weighing less than 35 kg. |
| 5-7 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients weighing less than 35 kg. |
| 8-10 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients weighing less than 35 kg. |
| 11-15 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients weighing less than 35 kg. |
| 16-20 kg | Not recommended | Not applicable | Safety and efficacy have not been established in pediatric patients weighing less than 35 kg. |
Formulation
Purpose
Hepbest is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 12 years of age and older with compensated liver disease.
Generic Name
Tenofovir AlafenamideScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.